The Social Anxiety Disorder (SAD/Social Phobia) drugs in development market research report provides comprehensive information on the therapeutics under development for Social Anxiety Disorder (SAD/Social Phobia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Social Anxiety Disorder (SAD/Social Phobia). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Social Anxiety Disorder (SAD/Social Phobia) and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Social Anxiety Disorder (SAD/Social Phobia) by 16 companies/universities/institutes. The top development phase for Social Anxiety Disorder (SAD/Social Phobia) is phase ii with six drugs in that stage. The Social Anxiety Disorder (SAD/Social Phobia) pipeline has 15 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Social Anxiety Disorder (SAD/Social Phobia) pipeline products market are: Tonix Pharmaceuticals Holding, Boehringer Ingelheim International and Vanda Pharmaceuticals.
The key targets in the Social Anxiety Disorder (SAD/Social Phobia) pipeline products market include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1), Cannabinoid Receptor 2 (CB2 or CX5 or CNR2), and 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A).
The key mechanisms of action in the Social Anxiety Disorder (SAD/Social Phobia) pipeline product include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Agonist with three drugs in Phase III. The Social Anxiety Disorder (SAD/Social Phobia) pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Social Anxiety Disorder (SAD/Social Phobia) pipeline products market including Small Molecule, and Synthetic Peptide.
Social Anxiety Disorder (SAD/Social Phobia) overview
Social anxiety disorder (SAD), also known as social phobia, is an anxiety disorder characterized by sentiments of fear and anxiety in social situations, causing considerable distress and impairing ability to function in at least some aspects of daily life. These fears can be triggered by perceived or actual scrutiny from others.
For a complete picture of Social Anxiety Disorder (SAD/Social Phobia)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
